Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024

Aligos Therapeutics, Inc.

Matthew McClure resigned as Chief Medical Officer on May 9, 2024.
No replacement or interim CMO was announced in the filing.
The departure follows Aligos's focus on antiviral therapeutics; impact on pipeline unclear.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew McClure

Chief Medical Officer

ALGS · Aligos Therapeutics, Inc.

Effective: 2024-05-09
Filed: May 15, 2024, 7:59 PM ET

On May 9, 2024, Matthew McClure notified Aligos Therapeutics, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew McClure resigned as Chief Medical Officer at Aligos Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On May 9, 2024, Matthew McClure notified Aligos Therapeutics, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company.

View on SEC.gov

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-139476

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.